Literature DB >> 32588586

Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population

Allison Ching Yee Tso1, Christina Lai Lin Sum2, Kiat Hoe Ong1.   

Abstract

INTRODUCTION: ADAMTS13 (a disintegrin-like and metalloproteinase with a thrombospondin Type 1 motif, member 13) plays a fundamental role in the regulation of haemostasis and thrombosis. Its deficiency leads to an accumulation of ultra-large von Willebrand multimers, inducing spontaneous platelet aggregation, thrombosis in the microvasculature, and thrombotic thrombocytopenic purpura (TTP), a condition with 90% mortality when left untreated. Prompt quantification of ADAMTS13 antigen, activity and autoantibody plays a crucial role in the diagnosis and management of TTP and can help differentiate it from other thrombotic microangiopathies (TMAs). Reference ranges for ADAMTS13 are generally derived from Caucasian patients. Given that polymorphism in the ADAMTS13 gene can be associated with variable ADAMTS13 levels, we aimed to establish the first reference range in Singapore and provide a crucial laboratory test for institutions here and elsewhere.
METHODS: 150 healthy voluntary donors (75 men, 75 women) aged 21-60 years, with an ethnic mix mirroring Singapore's population profile, were recruited. ADAMTS13 antigen, activity and autoantibody levels were measured using the fluorescence resonance energy transfer-vWF73 and enzyme-linked immunosorbent assay methodologies.
RESULTS: Levels (activity 0.65-1.79 IU/mL, antigen 0.36-1.17 IU/mL, autoantibody 1.4-12.5 U/mL) were not statistically different between the genders and various age groups.
CONCLUSION: TTP and TMAs are encountered in a wide range of specialties. The availability of new assays in Singapore will aid clinicians in the timely management of these conditions. Standardising reference ranges established for Singapore against World Health Organization standards allows harmonisation of measurements between laboratories and for future research collaborations. Copyright: © Singapore Medical Association

Entities:  

Keywords:  ADAMTS13; microangiopathic haemolytic anaemia; thrombotic thrombocytopenic purpura

Mesh:

Substances:

Year:  2020        PMID: 32588586      PMCID: PMC9251263          DOI: 10.11622/smedj.2020093

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   3.331


  30 in total

1.  Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features.

Authors:  Marie Scully; Helen Yarranton; Ri Liesner; Jamie Cavenagh; Beverley Hunt; Sylvia Benjamin; David Bevan; Ian Mackie; Samuel Machin
Journal:  Br J Haematol       Date:  2008-07-08       Impact factor: 6.998

Review 2.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

3.  Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).

Authors:  Neil Shah; Cynthia Rutherford; Karen Matevosyan; Yu-Min Shen; Ravi Sarode
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

4.  How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.

Authors:  Spero R Cataland; Haifeng M Wu
Journal:  Blood       Date:  2014-03-05       Impact factor: 22.113

5.  Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Evaren E Page; Johanna A Kremer Hovinga; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2016-04-08       Impact factor: 22.113

6.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

Authors:  Silvia Ferrari; Friedrich Scheiflinger; Manfred Rieger; Geert Mudde; Martine Wolf; Paul Coppo; Jean-Pierre Girma; Elie Azoulay; Christian Brun-Buisson; Fadi Fakhouri; Jean-Paul Mira; Eric Oksenhendler; Pascale Poullin; Eric Rondeau; Nicolas Schleinitz; Benoit Schlemmer; Jean-Louis Teboul; Philippe Vanhille; Jean-Paul Vernant; Dominique Meyer; Agnès Veyradier
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 7.  ADAMTS13 activity and genetic mutations in Japan.

Authors:  T Miyata; K Kokame; M Matsumoto; Y Fujimura
Journal:  Hamostaseologie       Date:  2013-05-29       Impact factor: 1.778

Review 8.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

9.  Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.

Authors:  Bert-Jan H van den Born; Niels V van der Hoeven; Evelyn Groot; Peter J Lenting; Joost C M Meijers; Marcel Levi; Gert A van Montfrans
Journal:  Hypertension       Date:  2008-03-10       Impact factor: 10.190

10.  Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.

Authors:  Yoshitaka Mori; Hideo Wada; Esteban C Gabazza; Nobuyuki Minami; Tsutomu Nobori; Hiroshi Shiku; Hideo Yagi; Hiromichi Ishizashi; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.